Strength peptides for women: dosing and stack differences
Female lifters running peptides should not just halve the male protocols. Body comp, hormonal context, and side-effect risk all shift the dosing math meaningfully.
May 8, 2026 · 7 min read · By Strength Peptide Editors
Most strength-peptide protocols you'll find online assume the user is a 175–225 lb man. That's not malicious — it reflects who has been writing about peptides for the longest time. But it does mean that a woman copying the standard advice is often dosing higher than her body-comp baseline justifies, ignoring hormonal context that meaningfully changes how the peptides act, and underweighting side effects that hit harder at the same nominal dose. None of the strength peptides are unsafe for women at appropriate doses — but "appropriate" is not always "half the male dose."
What actually changes between men and women
Three variables move the dosing math.
Lean body mass. Most peptides — BPC-157, TB-500, ipamorelin, MK-677 — are dosed in raw micrograms or milligrams, not per-kilogram. A 150 lb woman has roughly 60–70% the lean mass of a 200 lb man. A "standard" 250 mcg BPC-157 dose at her body comp behaves like ~360 mcg in his. That's not categorically dangerous, but it shifts where she sits on the dose-response curve.
Hormonal context. Estrogen, progesterone, and the menstrual cycle alter how several peptide families act:
- GH secretagogues — endogenous GH pulses are larger and more variable in pre-menopausal women, partly because of estrogen's positive effect on GH secretion. Adding ipamorelin/CJC-1295 on top of an already-active axis can produce more pronounced acute responses.
- IGF-1 family — IGF-1 signaling interacts with estrogen receptor pathways. Hypoglycemia risk on IGF-1 LR3 may be more pronounced in the luteal phase, when fasting glucose tends to be lower.
- Glucose handling — insulin sensitivity shifts across the menstrual cycle. MK-677-induced fasting-glucose elevation is more variable in women.
- Thyroid axis — estrogen affects TBG (thyroid-binding globulin); peptides that interact with the GH/IGF-1 axis can produce thyroid-axis ripples that women feel earlier than men do.
Side-effect threshold. Several peptide side effects — water retention, joint pain on a GH cycle, carpal-tunnel-style symptoms — appear at lower doses in women on average. This is partly body-mass scaling, partly fluid-distribution differences, partly receptor-density factors. The practical implication: starting doses should run lower, and dose escalation should be slower.
What the dose ranges actually look like
These are practical starting ranges that match what women in the strength community typically run successfully. They are not prescriptions; clinical context still matters.
| Peptide | Typical female start | Typical female ceiling | Notes |
|---|---|---|---|
| BPC-157 | 150–200 mcg subQ daily | 250 mcg subQ daily | Dose near injury site; full male protocols often work, just a touch lower |
| TB-500 | 1.5–2.5 mg twice weekly (loading), then every 1–2 weeks | 2.5–3 mg same cadence | Loading phase reaches saturation faster |
| Ipamorelin | 100–200 mcg subQ pre-bed | 250 mcg | Pre-bed timing is even more important; pulse is sharper |
| CJC-1295 (no DAC) | 50–100 mcg with ipamorelin | 200 mcg | Stack rather than solo |
| CJC-1295 DAC | 0.5–1 mg per week | 2 mg per week | DAC variant accumulates; conservative dosing matters more |
| Sermorelin | 150–300 mcg pre-bed | 500 mcg | Often easier-to-tolerate first GH option |
| MK-677 (ibutamoren) | 5–10 mg oral, pre-bed | 15 mg | Hunger and water retention scale fast in women |
| IGF-1 LR3 | 15–25 mcg subQ daily | 40 mcg | Hypoglycemia awareness is non-optional |
| GHK-Cu | 1–2 mg subQ 2× weekly | 3 mg same | Topical 2–3% solution for skin/hair use; subQ for systemic recovery |
| Tesamorelin | 1 mg subQ daily | 2 mg subQ daily | Half the standard FDA-approved male dose is a common starting point |
A general rule: start at the bottom of your range, hold for two weeks, then evaluate before going up. Most of the meaningful side effects show up in week 1–2.
Stack-level differences
The stacking math also shifts.
The "BPC-157 + TB-500" recovery stack holds up well for women — both peptides scale cleanly with body mass, and the combination is no more risky than for men. See can I stack BPC-157 with TB-500.
The "ipamorelin + CJC-1295" GH stack is generally tolerated well at female-adjusted doses. The thing to watch is sleep quality — if the stack pushes deep-sleep duration past the user's natural baseline, mornings can feel groggy, and that effect lands earlier in women than men in many anecdotal reports.
IGF-1 LR3 layered on top of a GH stack is where female protocols deserve more conservative scaling. The combined IGF-1 elevation (from endogenous GH pulses + exogenous LR3) compounds, and hypoglycemia management becomes critical. See hypoglycemia on IGF-1 LR3.
Stacks involving MK-677 require the most adjustment. The hunger and water-retention effects scale up faster in women, and the body-comp downsides can outweigh the recovery benefits if the dose is set by a male reference protocol. Either drop the dose meaningfully or use ipamorelin + CJC-1295 instead.
Goal-based protocol skeletons
These are framing examples, not detailed prescriptions.
Recovery-focused (tendinopathy, soft-tissue injury):
- BPC-157 200 mcg subQ daily near the affected tissue for 6–8 weeks
- Optional: TB-500 2 mg twice weekly for first 4 weeks
- No GH layer needed; recovery peptides do the job
- Cost: relatively low; sourcing risk is the main variable
Body composition during a cut:
- Tesamorelin 1 mg subQ daily, 12 weeks (visceral-fat focus); see tesamorelin: visceral fat literature
- Or ipamorelin 200 mcg + CJC-1295 (no DAC) 100 mcg pre-bed
- Strict nutrition baseline does 80%+ of the work; peptides are the layer on top
- Avoid MK-677 unless willing to manage hunger and water retention
Recomposition with active strength training:
- IGF-1 LR3 20 mcg subQ daily — start there, don't escalate quickly
- BPC-157 150–200 mcg subQ daily for joint/tendon support
- Optional: ipamorelin + CJC-1295 pre-bed for sleep-pulse support
- Mandatory: tracking fasting glucose, sleep, recovery quality
- Lab work before and after; see baseline labs before a cycle
Sleep and recovery for hard-training masters athletes:
- Sermorelin 200–300 mcg pre-bed, 8–12 weeks; see sermorelin for sleep quality
- BPC-157 as needed for specific issues
- Lower priority on IGF-1 LR3 unless body-comp is also a goal
Pregnancy, breastfeeding, fertility
This is the non-negotiable part. Strength peptides are not appropriate during pregnancy or breastfeeding, and women trying to conceive should treat them with the same seriousness as any other research-chemical compound. Hormonal-axis peptides — GH secretagogues, IGF-1 family, sermorelin — have plausible effects on fertility cycles that are not characterized in human pregnancy. See peptides during pregnancy and breastfeeding for the full discussion.
If you are using hormonal contraception, the interaction picture is also unclear. There's no specific signal that GH secretagogues reduce contraceptive efficacy, but the evidence for no effect doesn't exist either.
What to do
The practical playbook for a woman starting peptides:
- Define one clear goal — recovery, body composition, sleep — and pick the protocol that targets it specifically. Don't combine goals in a first cycle.
- Start at the bottom of the female dose range and hold for two weeks before evaluating.
- Pull baseline labs — CBC, CMP, fasting glucose, lipid panel, and a basic hormone panel including thyroid. See baseline labs before a cycle.
- Track the menstrual cycle while running peptides — symptom intensity, sleep quality, hunger, mood — and treat unexpected cycle changes as a "stop and reassess" signal.
- Use a single-vendor supply with current Certificates of Analysis. Variability between vendors is one of the most common reasons female users see inconsistent effects.
Strength peptides work for women — sometimes better than for men, when the protocol respects the differences. The path that doesn't work is treating "the standard protocol" as if it were universal. It isn't.
Related reading
Free weekly newsletter
Get the strength peptide highlights, weekly.
One short email a week — new guides, study readouts, supply updates, and dosing tips. Plain-English, no spam.
Unsubscribe anytime. We never share your email.